Immutep Limited (IMMP)
After hours:
| Previous close | 2.9800 |
| Open | 2.6800 |
| Bid | 2.6100 x 400 |
| Ask | 2.6400 x 300 |
| Day's range | 2.4500 - 2.7000 |
| 52-week range | 1.5800 - 3.3400 |
| Volume | |
| Avg. volume | 238,846 |
| Market cap | 326.91M |
| Beta (5Y monthly) | 1.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings date | 28 July 2024 - 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.33 |
GlobeNewswireImmutep successfully completes institutional placement and institutional component of entitlement offer
Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) (Immutep or the Company) is pleased to announce the successful completion of its institutional placement (Placement) and the institutional component (Institutional Entitlement Offer) of its 1 for 16 pro rata accelerated non-renounceable entitlement offer (Entitlement Offer and, together with the Placement, the Offer) of new fully paid ordinary shares in Immutep (New Shares). The Placemen
- GlobeNewswire
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)TACTI-004 Phase III trial will enrol approximately 750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapyUnder the collaboration, Immutep will conduct the registrational TACTI-004 Phase III trial and MSD will supply KEYTRUDAImmutep retains commercial rights
Simply Wall St.Immutep's (ASX:IMM) investors will be pleased with their notable 73% return over the last five years
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
